Drug intelligence / Profile preview

SON-2014

Development stage: Unknown
Lead developer: Sonnet BioTherapeutics
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

SON-2014, also known as GMCSF-F HAB-IL18, is a drug developed by Sonnet BioTherapeutics. It was designed to stimulate granulocyte-macrophage colony-stimulating factor (GM-CSF) and incorporate interleukin-18 (IL-18) using the Fully Human Albumin Binding (F HAB) platform, which extends drug half-life. However, it has been discontinued in favor of SON-1410.

Other names: GMCSF-F HAB-IL18

Targets

gp60 (GP60 Receptor)IL-18R (Interleukin-18 receptor complex)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)SPARC (Secreted protein acidic and rich in cysteine)

Beyond the preview

Go deeper on SON-2014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SON-2014.

Explore the full profile